Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

PURPOSE: Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2(+)) metastatic breast cancer (MBC) who had receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M., Waters, Simon H., Hurvitz, Sara A., Moy, Beverly, Kim, Sung-Bae, Gradishar, William J., Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J., Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S., Bryce, Richard, Vivancos, Ana, Eli, Lisa D., Delaloge, Suzette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401509/
https://www.ncbi.nlm.nih.gov/pubmed/34380637
http://dx.doi.org/10.1158/1078-0432.CCR-21-1584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401509/
https://www.ncbi.nlm.nih.gov/pubmed/34380637
http://dx.doi.org/10.1158/1078-0432.CCR-21-1584

Ejemplares similares